Ruxolitinib with Navitoclax Is Efficacious and Safe in Myelofibrosis

0Citations
Citations of this article
1Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The primary endpoint of 35% or greater reduction in spleen volume was met with manageable safety.

Cite

CITATION STYLE

APA

Ruxolitinib with Navitoclax Is Efficacious and Safe in Myelofibrosis. (2022). Cancer Discovery, 12(5), OF4. https://doi.org/10.1158/2159-8290.CD-RW2022-037

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free